According to the 2020 CSCO guidelines for non-small-cell lung cancer (7), the first-line treatment for LUAD with EGFR exon 20 mutation is chemotherapy plus bevacizumab. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.